Neurocrine Biosciences (NBIX) Competitors $117.44 -5.44 (-4.43%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NBIX vs. XLRN, TECH, QGEN, MNTA, ALNY, BIIB, UTHR, INCY, BMRN, and EXELShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Acceleron Pharma (XLRN), Bio-Techne (TECH), Qiagen (QGEN), Momenta Pharmaceuticals (MNTA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "medical" sector. Neurocrine Biosciences vs. Acceleron Pharma Bio-Techne Qiagen Momenta Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences (NASDAQ:NBIX) and Acceleron Pharma (NASDAQ:XLRN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Does the media refer more to NBIX or XLRN? In the previous week, Neurocrine Biosciences had 13 more articles in the media than Acceleron Pharma. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 0 mentions for Acceleron Pharma. Neurocrine Biosciences' average media sentiment score of 0.93 beat Acceleron Pharma's score of 0.00 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Overall Sentiment Neurocrine Biosciences Positive Acceleron Pharma Neutral Which has better earnings & valuation, NBIX or XLRN? Neurocrine Biosciences has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.24B5.30$249.70M$3.7331.49Acceleron Pharma$92.52M118.15-$166.03M-$4.21-42.46 Does the MarketBeat Community believe in NBIX or XLRN? Neurocrine Biosciences received 440 more outperform votes than Acceleron Pharma when rated by MarketBeat users. Likewise, 77.39% of users gave Neurocrine Biosciences an outperform vote while only 63.12% of users gave Acceleron Pharma an outperform vote. CompanyUnderperformOutperformNeurocrine BiosciencesOutperform Votes101077.39% Underperform Votes29522.61% Acceleron PharmaOutperform Votes57063.12% Underperform Votes33336.88% Is NBIX or XLRN more profitable? Neurocrine Biosciences has a net margin of 17.21% compared to Acceleron Pharma's net margin of -226.01%. Neurocrine Biosciences' return on equity of 15.68% beat Acceleron Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences17.21% 15.68% 11.38% Acceleron Pharma -226.01%-32.11%-29.45% Do analysts rate NBIX or XLRN? Neurocrine Biosciences presently has a consensus target price of $163.91, suggesting a potential upside of 39.57%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Acceleron Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Acceleron Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, NBIX or XLRN? Neurocrine Biosciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Do institutionals & insiders have more ownership in NBIX or XLRN? 92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 90.4% of Acceleron Pharma shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 1.7% of Acceleron Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryNeurocrine Biosciences beats Acceleron Pharma on 18 of the 19 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.89B$2.91B$5.07B$8.66BDividend YieldN/A1.79%5.10%4.06%P/E Ratio31.4941.61100.6017.27Price / Sales6.30217.681,195.1369.06Price / Cash45.54178.0141.0336.35Price / Book4.374.096.345.87Net Income$249.70M-$42.42M$119.64M$225.66M7 Day Performance-6.60%-10.63%-5.13%-1.34%1 Month Performance-0.86%-5.81%-2.72%1.15%1 Year Performance7.80%24.19%31.10%24.02% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.9632 of 5 stars$117.44-4.4%$163.91+39.6%+8.0%$11.89B$1.89B31.491,400XLRNAcceleron PharmaN/A$178.75flatN/AN/A$10.93B$92.52M-42.46312TECHBio-Techne4.8317 of 5 stars$67.57-6.9%N/A+11.0%$10.74B$1.16B71.883,100Analyst UpgradeHigh Trading VolumeQGENQiagen4.2892 of 5 stars$41.27-1.9%N/A+1.6%$9.42B$1.97B105.825,967Analyst RevisionMNTAMomenta PharmaceuticalsN/A$52.48flatN/AN/A$6.25B$23.87M-24.75131ALNYAlnylam Pharmaceuticals4.8194 of 5 stars$235.56-8.7%N/A+39.4%$30.38B$1.83B-89.912,100Analyst DowngradeShort Interest ↓Gap DownHigh Trading VolumeBIIBBiogen4.8855 of 5 stars$159.99-3.0%N/A-30.3%$23.31B$9.84B14.457,570Analyst UpgradeNews CoverageUTHRUnited Therapeutics4.5087 of 5 stars$363.25-6.0%N/A+60.3%$17.24B$2.33B15.951,168Insider SellingNews CoveragePositive NewsINCYIncyte4.1835 of 5 stars$75.87-2.4%N/A+40.5%$14.62B$3.70B541.972,524Analyst ForecastPositive NewsBMRNBioMarin Pharmaceutical4.9905 of 5 stars$63.42-3.3%N/A-27.3%$12.09B$2.42B37.983,401Analyst ForecastInsider SellingNews CoverageEXELExelixis4.7676 of 5 stars$34.45-1.7%N/A+64.2%$9.84B$2.08B22.081,310Short Interest ↓ Related Companies and Tools Related Companies Acceleron Pharma Competitors Bio-Techne Competitors Qiagen Competitors Momenta Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBIX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
